|
| 35102438 | Immune Responses to Varicella-Zoster Virus Vaccines. | Current Topics in Microbiology and Immunology | 2023 |
| 36411267 | AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019. | Clin Infect Dis | 2023 |
| 37788096 | Recruitment of naive CD4+ T cells by the recombinant zoster vaccine correlates with persistent immunity. | | 2023 |
| 37280116 | Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants. | | 2023 |
| 37141390 | Predictors of 5-Year Persistence of Antibody Responses to Zoster Vaccines. | | 2023 |
| 37328350 | Incidence and clinical outcomes of pneumonia in persons with down syndrome in the United States. | | 2023 |
| 34699616 | Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis. | Am J Hematol | 2022 |
| 35651955 | Balancing risk and benefit of SARS-CoV-2 vaccines in children. | Lancet Regional Health - Europe, The | 2022 |
| 35443106 | Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19. | New England Journal of Medicine | 2022 |
| 36284110 | Development of antibody-dependent cellular cytotoxicity in response to recombinant and live-attenuated herpes zoster vaccines. | npj Vaccines | 2022 |
| 35749312 | Risk of Severe Coronavirus Disease 2019 Disease in Individuals With Down Syndrome: A Matched Cohort Study From a Large, Integrated Health Care System. | Journal of Infectious Diseases | 2022 |
| 34850039 | Cell-Mediated Immune Responses After Administration of the Live or the Recombinant Zoster Vaccine: 5-Year Persistence. | Journal of Infectious Diseases | 2022 |
| 35028334 | A Real-World Clinical and Economic Analysis of Cell-Derived Quadrivalent Influenza Vaccine Compared to Standard Egg-Derived Quadrivalent Influenza Vaccines During the 2019-2020 Influenza Season in the United States. | Open Forum Infectious Diseases | 2022 |
| 34662415 | Association Between Immunogenicity and Reactogenicity: A Post Hoc Analysis of 2 Phase 3 Studies With the Adjuvanted Recombinant Zoster Vaccine. | Journal of Infectious Diseases | 2022 |
| 34696254 | Comparing the Clinical and Economic Outcomes Associated with Adjuvanted versus High-Dose Trivalent Influenza Vaccine among Adults Aged â¿¥ 65 Years in the US during the 2019-20 Influenza Season-A Retrospective Cohort Analysis. | Vaccines | 2021 |
| 33619170 | Vaccines for older adults. | BMJ, The | 2021 |
| 33762414 | Comparative Antibody Responses to the Live-Attenuated and Recombinant Herpes Zoster Vaccines. | Journal of Virology | 2021 |
| 32530462 | Impact of Reactogenicity After Two Doses of Recombinant Zoster Vaccine Upon Physical Functioning and Quality of Life: An Open Phase III Trial in Older Adults. | | 2021 |
| 33197294 | Recombinant Zoster Vaccine Is Efficacious and Safe in Frail Individuals. | | 2021 |
| 32910152 | Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials. | Rheumatology | 2021 |
| 34551225 | Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. | N Engl J Med | 2021 |
| 31618437 | Adjuvanted Recombinant Glycoprotein E Herpes Zoster Vaccine. | Clinical Infectious Diseases | 2020 |
| 32305975 | Herpes Zoster and Its Prevention by Vaccination. | Interdisciplinary Topics in Gerontology and Geriatrics | 2020 |
| 32119591 | Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trial. | Human Vaccines and Immunotherapeutics | 2020 |
| 31774916 | Safety and Varicella Outcomes in In Utero-Exposed Newborns and Preterm Infants Treated With Varicella Zoster Immune Globulin (VARIZIG): A Subgroup Analysis of an Expanded-Access Program. | Journal of the Pediatric Infectious Diseases Society | 2020 |
| 32347767 | Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials. | Human Vaccines and Immunotherapeutics | 2020 |
| 31003070 | Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine. | | 2019 |
| 30165651 | Persistence of Varicella-Zoster Virus Cell-Mediated Immunity After the Administration of a Second Dose of Live Herpes Zoster Vaccine. | Journal of Infectious Diseases | 2019 |
| 30256905 | The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III Trial. | | 2019 |
| 30146405 | A double-blind, randomized, controlled, multi-center safety and immunogenicity study of a refrigerator-stable formulation of VARIVAX®. | Vaccine | 2019 |
| 29955836 | Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and Older. | | 2019 |
| 31092579 | The Effect of Age on the Immunogenicity of the Live Attenuated Zoster Vaccine Is Predicted by Baseline Regulatory T Cells and Varicella-Zoster Virus-Specific T Cell Immunity. | Journal of Virology | 2019 |
| 31269033 | Varicella zoster immune globulin (VARIZIG) administration up to 10 days after varicella exposure in pregnant women, immunocompromised participants, and infants: Varicella outcomes and safety results from a large, open-label, expanded-access program. | PLoS ONE | 2019 |
| 30852939 | Antibody and B cell responses to an investigational adjuvanted RSV vaccine for older adults. | Human Vaccines and Immunotherapeutics | 2019 |
| 30685248 | Costs of herpes zoster complications in older adults: A cohort study of US claims database. | Vaccine | 2019 |
| 31216205 | Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials. | Human Vaccines and Immunotherapeutics | 2019 |
| 30676834 | Immune responses to zoster vaccines. | Human Vaccines and Immunotherapeutics | 2019 |
| 31157595 | Evaluation of two frailty indices, with practical application in a vaccine clinical trial. | Human Vaccines and Immunotherapeutics | 2019 |
| 29494593 | The epidemiology of adolescents living with perinatally acquired HIV: A cross-region global cohort analysis. | PLoS Medicine | 2018 |
| 28830693 | Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine. | Vaccine | 2018 |
| 30024861 | Th1 memory differentiates recombinant from live herpes zoster vaccines. | Journal of Clinical Investigation | 2018 |
| 30249425 | Cost of herpes zoster and herpes zoster-related complications among immunocompromised individuals. | Vaccine | 2018 |
| 30247596 | Comparative Immune Responses to Licensed Herpes Zoster Vaccines. | Journal of Infectious Diseases | 2018 |
| 30247592 | Herpes Zoster Vaccines. | Journal of Infectious Diseases | 2018 |
| 30053655 | Varicella-zoster virus inhibits autophagosome-lysosome fusion and the degradation stage of mTOR-mediated autophagic flux. | Virology | 2018 |
| 30179984 | Herpes Zoster and Herpes Zoster Vaccine Rates Among Adults Living With and Without HIV in the Veterans Aging Cohort Study. | J Acquir Immune Defic Syndr | 2018 |
| 29762690 | Intestinal Integrity Biomarkers in Early Antiretroviral-Treated Perinatally HIV-1-Infected Infants. | Journal of Infectious Diseases | 2018 |
| 29529222 | Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older. | Journal of Infectious Diseases | 2018 |
| 29661022 | Low Rates of Vaccination for Herpes Zoster in Older People Living With HIV. | AIDS Research and Human Retroviruses | 2018 |
| 29424778 | Persistence of memory B-cell and T-cell responses to the quadrivalent HPV vaccine in HIV-infected children. | AIDS | 2018 |